Mike Montemarano, Associate Editor 04.12.21
Nutraceutical developer Thorne Healthtech announced today that it has entered a strategic partnership with PreCon Health, Inc., a supplement company specializing in supplements to support brain function, in order to bring to market the first multi-ingredient dietary supplements formulated to support pre- and post-impact brain health.
“We are excited to be partnering with PreCon Health, Inc. to bring to market PreCon Health’s pre- and post-impact brain health supplements, SynaQuell and SynaQuell+, Thorne’s first venture into brain health,” Paul Jacobson, CEO of Thorne HealthTech, said. “Their extensive neurological expertise, coupled with Thorne HealthTech’s testing and manufacturing capabilities, allows us to apply our unique insights and tools to provide solutions addressing impact-related brain health, a considerable public health concern in the U.S.”
PreCon Health’s patent-pending formulations leverage extensive research to target multiple pathological mechanisms known to contribute to the effects of impact on brain health. SynaQuell is a proprietary, to-be-declared multi-ingredient formulation designed to support healthy brain function, reduce inflammation, and promote cellular energy function, while SynaQuell+ is intended for the same purposes but following potential impact, the company said.
“Thorne's commitment to rigorous science and comprehensive testing from start to finish make them a perfect partner for PreCon Health. The partnership will leverage Thorne's commitment and ability to develop supplement formulas of the highest quality," David Dodick, MD, Professor of Neurology and Chair of Precon Health, said. "I am excited that PreCon Health and Thorne will be working together to address this significant need in the field of brain health, bringing to bear the data-driven, innovative health solutions that Thorne Healthtech is able to provide.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
“We are excited to be partnering with PreCon Health, Inc. to bring to market PreCon Health’s pre- and post-impact brain health supplements, SynaQuell and SynaQuell+, Thorne’s first venture into brain health,” Paul Jacobson, CEO of Thorne HealthTech, said. “Their extensive neurological expertise, coupled with Thorne HealthTech’s testing and manufacturing capabilities, allows us to apply our unique insights and tools to provide solutions addressing impact-related brain health, a considerable public health concern in the U.S.”
PreCon Health’s patent-pending formulations leverage extensive research to target multiple pathological mechanisms known to contribute to the effects of impact on brain health. SynaQuell is a proprietary, to-be-declared multi-ingredient formulation designed to support healthy brain function, reduce inflammation, and promote cellular energy function, while SynaQuell+ is intended for the same purposes but following potential impact, the company said.
“Thorne's commitment to rigorous science and comprehensive testing from start to finish make them a perfect partner for PreCon Health. The partnership will leverage Thorne's commitment and ability to develop supplement formulas of the highest quality," David Dodick, MD, Professor of Neurology and Chair of Precon Health, said. "I am excited that PreCon Health and Thorne will be working together to address this significant need in the field of brain health, bringing to bear the data-driven, innovative health solutions that Thorne Healthtech is able to provide.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
